Key Findings
- In 10,980 ER-positive breast cancers profiled by Caris, high TONSL expression was associated with poorer outcomes following endocrine therapy and CDK4/6 inhibition, supporting further study of TONSL-directed strategies in resistant disease.
- This study demonstrates how integrated genomic, transcriptomic, and immune profiling can identify biologically distinct breast cancer subgroups, refine therapeutic stratification, and uncover potential biomarkers of treatment response and resistance across metastatic, hormone receptor–positive, and triple-negative disease.